Compass Therapeutics (CMPX) PT Lowered to $4 at Citizens After FDA Dialogue

September 23, 2026 4:31 AM EDT Send to a Friend
Citizens analyst Reni Benjamin lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $4.00 (from $10.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login